Tannenbaum Cara, Sheehan Nancy L
Université de Montreal, Centre de Recherche de l'Institut universitaire de gériatrie de Montréal, 4565 Queen Mary Road #4824, Montreal, Québec H3W 1W5, Canada.
Expert Rev Clin Pharmacol. 2014 Jul;7(4):533-44. doi: 10.1586/17512433.2014.910111. Epub 2014 Apr 19.
Concomitant administration of multiple drugs can lead to unanticipated drug interactions and resultant adverse drug events with their associated costs. A more thorough understanding of the different cytochrome P450 isoenzymes and drug transporters has led to new methods to try to predict and prevent clinically relevant drug interactions. There is also an increased recognition of the need to identify the impact of pharmacogenetic polymorphisms on drug interactions. More stringent regulatory requirements have evolved for industry to classify cytochrome inhibitors and inducers, test the effect of drug interactions in the presence of polymorphic enzymes, and evaluate multiple potentially interacting drugs simultaneously. In clinical practice, drug alert software programs have been developed. This review discusses drug interaction mechanisms and strategies for screening and minimizing exposure to drug interactions. We also provide future perspectives for reducing the risk of clinically significant drug interactions.
多种药物同时使用可能导致意想不到的药物相互作用以及由此产生的药物不良事件及其相关费用。对不同的细胞色素P450同工酶和药物转运体有了更深入的了解,从而产生了新的方法来尝试预测和预防临床相关的药物相互作用。人们也越来越认识到需要确定药物遗传多态性对药物相互作用的影响。监管要求变得更加严格,促使制药行业对细胞色素抑制剂和诱导剂进行分类,测试多态酶存在时药物相互作用的效果,并同时评估多种潜在相互作用的药物。在临床实践中,已经开发了药物警报软件程序。本综述讨论了药物相互作用机制以及筛选和尽量减少药物相互作用暴露的策略。我们还提供了降低临床显著药物相互作用风险的未来展望。